Effectiveness and Safety of PD-1 Inhibitor Monotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Exploratory Study

Table 1

Baseline and demographic characteristics of the 68 elderly patients with advanced NSCLC.

Baseline characteristics	Total (N = 68)	Percentage (%)
Age (year)
Median (range)	72 (65–82)
Gender
Male	43	63.2
Female	25	36.8
ECOG performance status
0–1	47	69.1
2	21	30.9
Pathological staging
IIIb	8	11.8
IV	60	88.2
Smoking status
Nonsmoker/former smoker	49	72.1
Smoker	19	27.9
Histology
Adenocarcinoma	38	55.9
Squamous cell carcinoma	30	44.1
Lines of PD-1 blockade therapy
Second line	13	19.1
Third line or more	55	80.9
Number of metastatic lesions
≤3	45	66.2
>3	23	33.8
History of targeted drug therapy
Yes	32	47.1
No	36	52.9
PD-1 blockades
Camrelizumab	23	33.8
Sintilimab	20	29.4
Pembrolizumab	16	23.5
Nivolumab	9	13.2

NSCLC, non-small cell lung cancer; PFS, progression-free survival; ECOG, Eastern Cooperative Oncology Group; PD-1, programmed cell death protein 1.